Ticker > Company >

Sun Pharma Adv. Res share price

Sun Pharma Advanced Research Company Ltd.

NSE: SPARC BSE: 532872 SECTOR: Business Support  1.34 L   221   24

146.00
+0.15 (0.10%)
BSE: 22 Aug 04:01 PM

Price Summary

Today's High

₹ 146.55

Today's Low

₹ 144.05

52 Week High

₹ 240.95

52 Week Low

₹ 109.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

4738.02 Cr.

Enterprise Value

4995.01 Cr.

No. of Shares

32.45 Cr.

P/E

0

P/B

0

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  -8.4

CASH

1.19 Cr.

DEBT

258.19 Cr.

Promoter Holding

65.67 %

EPS (TTM)

₹  -9.26

Sales Growth

-5%

ROE

0 %

ROCE

-321.18%

Profit Growth

11.05 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-5%
3 Year-19.44%
5 Year-1.35%

Profit Growth

1 Year11.05%
3 Year-32.86%
5 Year-2.2%

ROE%

1 Year0%
3 Year-88.49%
5 Year-53.09%

ROCE %

1 Year-321.18%
3 Year-167.84%
5 Year-196.64%

Debt/Equity

-1.1703

Price to Cash Flow

-13.07

Interest Cover Ratio

-37.7642

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 65.67 0.00
Mar 2025 65.67 0.00
Dec 2024 65.67 0.00
Sep 2024 65.67 2.78
Jun 2024 65.67 2.78
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 80.3274 days.
  • The company has a high promoter holding of 65.67%.

 Limitations

  • The company has shown a poor profit growth of -32.8561429198562% for the Past 3 years.
  • The company has shown a poor revenue growth of -19.4366417301319% for the Past 3 years.
  • Company has a poor ROE of -88.4851666666667% over the past 3 years.
  • Company has a poor ROCE of -167.8379% over the past 3 years
  • Company has negative cash flow from operations of -362.409.
  • The company has a low EBITDA margin of -253.92156% over the past 5 years.
  • The company has negative book value.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 16.81 12.86 14.91 27.19 9.64
Total Expenditure 111.93 116.71 89.29 81.11 61.97
Operating Profit -95.12 -103.85 -74.38 -53.92 -52.33
Other Income 1.56 0.04 0.19 0 9.02
Interest 0.52 1.11 2.77 4.51 6.18
Depreciation 2.76 2.77 2.75 2.55 2.54
Exceptional Items 0 0 0 0 0
Profit Before Tax -96.84 -107.69 -79.71 -60.98 -52.03
Tax 0 0 0 0 0
Profit After Tax -96.84 -107.69 -79.71 -60.98 -52.03
Adjusted EPS (Rs) -2.98 -3.32 -2.46 -1.88 -1.6

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 252.96 137.25 238.78 75.55 71.77
Total Expenditure 387.93 324 452.84 479.34 399.04
Operating Profit -134.98 -186.75 -214.06 -403.79 -327.28
Other Income 5.41 6.84 10.88 29.47 1.79
Interest 10.65 13.33 7.63 1.66 8.91
Depreciation 10.92 10.16 11.77 12.13 10.83
Exceptional Items 0 0 0 0 0
Profit Before Tax -151.14 -203.4 -222.58 -388.11 -345.22
Tax 0 0 0 0 0
Net Profit -151.14 -203.4 -222.58 -388.11 -345.22
Adjusted EPS (Rs.) -5.77 -7.48 -6.86 -11.96 -10.64

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 26.21 27.19 32.45 32.45 32.45
Total Reserves -194.46 4.04 480.32 92.4 -253.07
Borrowings 112.5 0 0 0 100
Other N/C liabilities 52.09 77.43 138.41 117.59 76.17
Current liabilities 233.35 171.43 178.95 243.89 373.72
Total Liabilities 229.69 280.08 830.13 486.33 329.28
Assets
Net Block 90.56 91.87 105.75 102.65 95.33
Capital WIP 5.23 3.72 1.87 1.27 0.56
Intangible WIP 0 22.65 25.13 42.53 53.59
Investments 0 0 0 0.42 0.42
Loans & Advances 70.64 67.83 64.8 67.67 128.19
Other N/C Assets 3.46 22.87 177.61 25.4 25.93
Current Assets 59.8 71.15 454.96 246.41 25.26
Total Assets 229.69 280.08 830.13 486.33 329.28
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -151.14 -203.4 -222.58 -388.11 -345.22
Adjustment 48.75 16.67 6.99 -11.33 18.83
Changes in Assets & Liabilities -47.88 -26.05 141.11 -25.88 -46.8
Tax Paid -1.63 4.54 5.37 -4.11 10.79
Operating Cash Flow -151.9 -208.23 -69.12 -429.43 -362.41
Investing Cash Flow 1.56 -29.17 -548.28 391.11 157.66
Financing Cash Flow 159.28 229.32 616.76 42.8 200.88
Net Cash Flow 8.95 -8.08 -0.64 4.48 -3.87

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 65.67 65.67 65.67 65.67 65.67
aalok dilip shanghvi 0.11 0.11 0.11 0.11 0.11
aditya medisales limited 1.51 1.51 1.51 1.51 1.51
dilip.s.shanghvi - - - 19.05 19.05
kumud shantilal shanghvi - - - 0.01 0.01
raksha sudhir valia - - - 1.28 1.28
shanghvi family & friends... - - - 0.05 0.05
shanghvi finance private ... - - - 42.28 42.28
sudhir vrundavandas valia... - - - 0.57 0.57
unimed investments limite... 0.39 0.39 0.39 0.39 0.39
vibha dilip shanghvi 0.33 0.33 0.33 0.33 0.33
vidhi dilip shanghvi 0.11 0.11 0.11 0.11 0.11
dilip shantilal shanghvi 19.05 19.05 19.05 - -
kumud s. shanghvi 0.01 0.01 0.01 - -
raksha s.valia 1.28 1.28 1.28 - -
shanghvi family & friends... 0.05 0.05 0.05 - -
shanghvi finance private ... 42.28 42.28 42.28 - -
sudhir valia 0.57 0.57 0.57 - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 34.33 34.33 34.33 34.33 34.33
enam holdings pvt ltd - - - 1.04 1.04
lakshdeep investments & f... 1.86 1.86 1.86 1.86 1.86
llp - - - 0.29 0.25
paresh mohanlal parekh 1.12 1.12 1.12 1.12 1.12
sun pharmaceutical indust... 3.18 3.18 3.18 3.18 3.18
vijay mohanlal parekh 1.13 1.13 1.13 1.13 1.13
enam securities private l... 1.04 1.04 1.04 - -
rekha jhunjhunwala - - 1.59 - -
jhunjhunwala rekha rakesh... 1.94 1.94 - - -

Annual Reports

Title Link
Title Link
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ACUITE RATINGS
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY22
Concall Q2FY25
Concall Q2FY24
Concall Q2FY21
Concall Q2FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q2FY25
Presentation Q2FY22
Presentation Q1FY21
Presentation Q1FY20
Presentation H1FY21

Company News

Sun Pharma Adv. Res - Quaterly Results 4 Aug, 2:10 PM Sun Pharma Adv. Res - Quaterly Results 4 Aug, 2:10 PM Sun Pharma Adv. Res - Quaterly Results 4 Aug, 2:10 PM Sun Pharma Advanced Research Company submits board meeting intimation 28 Jul, 5:11 PM Sun Pharma Advanced Research Company informs about AGM 19 Jul, 2:40 PM Sun Pharma Advanced Research incorporates wholly owned subsidiary 7 Jul, 9:12 AM Sun Pharma Advanced Research Company informs about newspaper advertisement 21 May, 5:07 PM Sun Pharma Adv. Res - Quaterly Results 19 May, 8:33 PM Sun Pharma Adv. Res - Quaterly Results 19 May, 8:33 PM Sun Pharma Advanced Research Company informs about trading window closure 27 Mar, 4:51 PM Sun Pharma Adv. Res - Quaterly Results 10 Feb, 7:56 PM Sun Pharma Adv. Res - Quaterly Results 10 Feb, 7:56 PM SPARC inks binding LoI with UCSF, Tiller 17 Dec, 11:08 AM Sun Pharma Advanced Research Company informs about press release 17 Dec, 9:46 AM Sun Pharma Adv. Res - Quaterly Results 4 Nov, 2:59 PM Sun Pharma Adv. Res - Quaterly Results 4 Nov, 2:59 PM Sun Pharma Adv. Res - Quaterly Results 4 Nov, 2:59 PM Sun Pharma Advanced Research Company informs about outcome of board meeting 5 Aug, 5:25 PM Sun Pharma Adv. Res - Quaterly Results 5 Aug, 2:24 PM Sun Pharma Adv. Res - Quaterly Results 5 Aug, 2:24 PM Sun Pharma Adv. Res - Quaterly Results 5 Aug, 2:24 PM Sun Pharma Adv. Res - Quaterly Results 24 May, 8:26 PM Sun Pharma Adv. Res - Quaterly Results 24 May, 8:26 PM Sun Pharma Advanced Research Company informs about compliance certificate 10 Apr, 4:06 PM Sun Pharma Advanced Research Company informs about press release 10 Apr, 9:59 AM Sun Pharma Advanced Research Company informs about loss of share certificates 7 Mar, 1:15 PM Sun Pharma Adv. Res - Quaterly Results 5 Feb, 1:49 PM Sun Pharma Adv. Res - Quaterly Results 5 Feb, 1:49 PM Sun Pharma Adv. Res - Quaterly Results 5 Feb, 1:49 PM Sun Pharma Advanced Research Company informs about clarification on price movement 4 Jan, 4:55 PM Sun Pharma Advanced Research Company informs about statement on deviation or variation 6 Nov, 5:14 PM Sun Pharma Adv. Res - Quaterly Results 6 Nov, 3:22 PM Sun Pharma Adv. Res - Quaterly Results 6 Nov, 3:22 PM Sun Pharma Adv. Res - Quaterly Results 6 Nov, 3:22 PM SPARC enters into agreement for SCD-153 with JHU and IOCB 2 Nov, 9:52 AM Sun Pharma Advanced Research Company informs about press release 30 Oct, 9:58 AM Sun Pharma Advanced Research Company informs about press release 19 Oct, 12:42 PM Sun Pharma Advanced Research Company informs about loss of share certificates 10 Oct, 5:17 PM Sun Pharma Advanced Research Company informs about details of loss of certificate 9 Oct, 5:08 PM SPARC incorporates wholly owned subsidiary in Delaware 26 Sep, 2:05 PM Sun Pharma Advanced Research Company informs about loss of share certificates 22 Sep, 12:54 PM Sun Pharma Adv. Res - Quaterly Results 7 Aug, 3:15 PM Sun Pharma Adv. Res - Quaterly Results 7 Aug, 3:15 PM Sun Pharma Adv. Res - Quaterly Results 7 Aug, 3:15 PM Sun Pharma Advanced Research Company informs about board meeting 29 Jul, 2:25 PM Sun Pharma Adv. Res - Quaterly Results 22 May, 1:39 PM Sun Pharma Adv. Res - Quaterly Results 22 May, 1:39 PM Sun Pharma Adv. Res - Quaterly Results 22 May, 1:39 PM Sun Pharma Advanced Research Company informs about details of loss of certificate 28 Apr, 1:00 PM Sun Pharma Advanced Research Company informs about loss of share certificates 18 Apr, 1:14 PM

Sun Pharma Adv. Res Stock Price Analysis and Quick Research Report. Is Sun Pharma Adv. Res an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Sun Pharma Adv. Res stock price today is Rs 146.08. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sun Pharma Adv. Res . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sun Pharma Adv. Res has a PE ratio of -15.7804904396673 which is low and comparatively undervalued .

  • Share Price: - The current share price of Sun Pharma Adv. Res is Rs 146.08. One can use valuation calculators of ticker to know if Sun Pharma Adv. Res share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sun Pharma Adv. Res has ROA of -84.6538 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sun Pharma Adv. Res has a Current ratio of 0.0676 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sun Pharma Adv. Res has a ROE of 0 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Sun Pharma Adv. Res has a Debt to Equity ratio of -1.1703 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Sun Pharma Adv. Res has reported revenue growth of -5.0027 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Sun Pharma Adv. Res for the current financial year is -456.033637098347 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sun Pharma Adv. Res is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sun Pharma Adv. Res is Rs -9.257 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sun Pharma Adv. Res in Ticker for free. Also, one can get the intrinsic value of Sun Pharma Adv. Res by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Sun Pharma Adv. Res
X